Invest Now
Products +
Pricing
Trading & Investing +
Calculators +
Support +
Learn +
IPO +
Partner
About us +
#AndekhaSach New
Login Open an account
Samco securities limited
Samco Star Rating Ads

Jenburkt Pharmaceuticals Ltd Share Price

₹ 0 (%)

Updated on 01-01-1970 5:30 AM

Stock Rating

Pros 4

 

Cons 4

Jenburkt Pharmaceuticals Ltd Price Performance

  • Day's Low
  • ₹0
  • Day's High
  • ₹0
₹ 0
  • 52-w low
  • ₹0
  • 52-w high
  • ₹0
0
  • Day's open
    ₹0
  • Previous close
    ₹0
  • VWAP
    ₹0
  • Lower price band
    ₹0
  • Upper price band
    ₹0

Today's Market Action

Its last traded stock price on BSE was 1,314 down by -0.96%. The total volume of shares on NSE and BSE combined was 2,495 shares. Its total combined turnover was Rs 0.33 crores.

Jenburkt Pharmaceuticals Ltd Medium and Long Term Market Action

The stock price of Jenburkt Pharmaceuticals Ltd is down by -100% over the last one month. Don't forget to check the full stock price history in the table below.

Jenburkt Pharmaceuticals Ltd Fundamentals

  • Market Cap (Cr): 528

  • Book Value (₹):

  • Stock P/E:

  • Revenue (Cr):

  • Total Debt (Cr):

  • Face Value (₹):

  • Roce (%):

  • ROE (%):

  • Earnings (Cr):

  • Promoter’s Holdings (%):

  • EPS (₹):

  • Debt to Equity:

  • Dividend Yield (%):

  • Cash (Cr):

Jenburkt Pharmaceuticals Ltd Mutual fund holdings and trends

FUND NAME Quantity Monthly Change (Qty)

Jenburkt Pharmaceuticals Ltd Shareholding Pattern

Similar Stocks

Company Price Market Cap (Cr) P/E

About Jenburkt Pharmaceuticals Ltd

Data not available.

Jenburkt Pharmaceuticals Ltd FAQ's

What is Share Price of Jenburkt Pharmaceuticals Ltd?

What is the Market Cap of Jenburkt Pharmaceuticals Ltd?

What is PE Ratio of Jenburkt Pharmaceuticals Ltd?

What is PB Ratio of Jenburkt Pharmaceuticals Ltd?

What is the CAGR of Jenburkt Pharmaceuticals Ltd?

How to Buy Jenburkt Pharmaceuticals Ltd Share?

Financials

(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

  • Above Average Sustainable RoE
    The company generates a sustainable return on equity greater than the expected cost of capital which implies that the underlying business can create and compound value over a period time due to it's ability to generate above average return on capital.
  • High Pricing Power
    The business enjoys a relatively high pricing power and is able to withstand competitive pressure which works as a great moat for equity shareholders of the company.
  • Asset Light Business
    The company operates a great asset light business with a high Asset turnover ratio of 9.86. A high asset turnover ratio is a great driver of RoE and can improve shareholder returns. A relatively higher asset turnover ratio also will result in lower dilution as the business grows its revenues as earnings.
  • Zero Debt
    The company has almost nil to negligible debt to equity ratio of 0.01. Considering the fact that the business is debt free, equity shareholders shall carry lower risk of holding the stock.

Cons

  • Poor Cash Flow Conversion
    The business has very poor cash conversion ratio of only 21.62% of operating earnings getting converted into operating cash flow. This implies that increase in profits has not translated into higher cash flows for the business and incrementally higher investments in working capital which works negatively for shareholders.
  • Highly Cyclical Industry
    The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
  • Poor Capital Allocation
    The company has disproportionately high amount of assets locked up in working capital, cash and cash equivalents, loans and advances, etc to the extent of 74.59 % of total assets. This reflects poorly on the capital allocation strategy of the management which negatively impacts shareholder returns.
  • Poor Corporate Governance
    The general corporate governance standards of the company are poor which can negatively impact shareholder value and returns.

Valuation Analysis

Margin of safety
(19/12/2024)
Stock Valuation
Dark green line
106
0%
0% People are bullish about Jenburkt Pharmaceuticals Ltd
0%
0 % People are bearish about Jenburkt Pharmaceuticals Ltd

What is your opinion about this Stock?

Historical Data

Samco Star Rating Ads

Jenburkt Pharmaceuticals Ltd

₹ 0 (%)

Brokerage & Taxes at Samco

Brokerage & Taxes at Other traditional broker

Potential Brokerage Savings with Samco ₹ 49.62()

Top Gainers (NIFTY 50)

Stock Name Change %

    Top Losers (NIFTY 50)

    Stock Name Change %

      ×

      Filing Complaints on SCORES

      Easy & quick Easy & quick

      1. Register on SCORES portal

      2. Mandatory details for filling complaints on SCORES

      Name | PAN | Address | Mobile | Number | E-mail ID

      3. Benefits

      Effective Communication

      Speedy redressal of the grievances

      Website Icon
      Open Free Account Now
      Open a Demat Account

      Free Trading & Demat Account

      +91